Published in J Thorac Oncol on January 01, 2015
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 | NCT01449461
Vandetanib in Advanced NSCLC With RET Rearrangement | NCT01823068
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer | NCT01233687
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors | NCT01804530
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer | NCT01951690
Sunitinib in Never-Smokers With Lung Adenocarcinoma | NCT01829217
A Phase 1 Study in Participants With Advanced Cancer | NCT01115790
AZD1775 for Advanced Solid Tumors | NCT01748825
Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN) (PIN) | NCT01788332
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer | NCT00019006
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects (Cancer) | NCT00955773
Preanalytic parameters in epidermal growth factor receptor mutation testing for non-small cell lung carcinoma: A review of cytologic series. Cancer Cytopathol (2015) 0.83
Functional role of eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) in NSCLC. Oncotarget (2016) 0.78
Lung Cancer Subtypes Generate Unique Immune Responses. J Immunol (2016) 0.78
[Diagnosis, prognosis, and prediction of non-small cell lung cancer : Importance of morphology, immunohistochemistry and molecular pathology]. Pathologe (2015) 0.77
Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg (2015) 0.77
RhoA inhibits apoptosis and increases proliferation of cultured SPCA1 lung cancer cells. Mol Med Rep (2017) 0.75
Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients. Oncotarget (2017) 0.75
The feasibility of molecular testing on cell blocks created from brush tip washings in the assessment of peripheral lung lesions. J Thorac Dis (2016) 0.75
Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients. Oncoimmunology (2016) 0.75
Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma. Thorac Cancer (2016) 0.75
Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis. Oncotarget (2016) 0.75
Sensitization strategies in lung cancer. Oncol Lett (2016) 0.75
MEK inhibitors against MET-amplified non-small cell lung cancer. Int J Oncol (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Sequencing technologies - the next generation. Nat Rev Genet (2009) 40.57
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94
International network of cancer genome projects. Nature (2010) 20.35
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 12.89
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
The DNA damage response: ten years after. Mol Cell (2007) 11.80
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 11.68
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 10.98
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol (2000) 9.76
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer (2010) 8.55
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene (2008) 6.82
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A (2005) 6.82
RET, ROS1 and ALK fusions in lung cancer. Nat Med (2012) 6.76
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol (2006) 6.55
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol (2014) 6.52
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 6.34
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res (2012) 6.23
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol (2012) 5.82
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res (2007) 5.75
Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet (2011) 5.70
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell (2002) 5.58
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med (2012) 5.31
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol (2012) 5.16
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A (2008) 5.08
The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell (2010) 5.06
Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med (2011) 4.94
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer (2006) 4.46
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
Tumor immunotherapy directed at PD-1. N Engl J Med (2012) 4.43
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature (2013) 4.43
PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer (2011) 4.37
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol (2013) 4.30
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell (1994) 4.10
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist (2009) 3.92
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology (2008) 15.86
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology (2003) 14.67
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
The genome of the African trypanosome Trypanosoma brucei. Science (2005) 11.48
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 10.87
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med (2005) 10.58
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
Akt stimulates aerobic glycolysis in cancer cells. Cancer Res (2004) 9.35
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol (2004) 8.83
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A (2010) 7.77
The American Board of Internal Medicine: evolving professional self-regulation. Ann Intern Med (2014) 7.65
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med (2015) 7.11
The DNA sequence of the human X chromosome. Nature (2005) 6.97
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med (2012) 6.90
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Lung cancer in never smokers: a review. J Clin Oncol (2007) 5.49
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40
Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol (2005) 5.29
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol (2012) 5.16
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol (2012) 5.16
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol (2004) 5.06
Literature Review of Florida Red Tide: Implications for Human Health Effects. Harmful Algae (2004) 5.00
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med (2002) 4.89
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med (2013) 4.74
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology (2006) 4.57
INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS. J Clin Oncol (2009) 4.53
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res (2007) 4.45
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res (2006) 4.11
Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol (2003) 4.07
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A (2011) 3.97
Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol (2011) 3.96
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature (2011) 3.90
Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol (2003) 3.84
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol (2008) 3.83
The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev (2003) 3.79
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 3.42
RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature (2012) 3.40
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res (2009) 3.38
Initial evaluation of the effects of aerosolized Florida red tide toxins (brevetoxins) in persons with asthma. Environ Health Perspect (2005) 3.38
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med (2006) 3.37
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov (2011) 3.34
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol (2011) 3.33
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
The preoperative incidence of raised intracranial pressure in nonsyndromic sagittal craniosynostosis is underestimated in the literature. J Neurosurg Pediatr (2014) 3.30
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res (2010) 3.30
Occupational exposure to aerosolized brevetoxins during Florida red tide events: effects on a healthy worker population. Environ Health Perspect (2005) 3.27
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25
Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc (2010) 3.25
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 3.23
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin (2006) 3.21
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20